International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

Article type

Null


Article page

16-22


Authors Details

Priyanka Chandel, Harish Uraon, Vivek Choudhary


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 456

PDF Downloaded: 83


Effect of Chemotherapy on Tumor Marker (Ca 15.3) and Serum in Breast Cancer Patients of Southern Eastern Region of Chhattisgarh; 6 Years Follow up Study


Null

Author Details : Priyanka Chandel, Harish Uraon, Vivek Choudhary

Volume : 3, Issue : , Year : 2016

Article Page : 16-22


Suggest article by email

Get Permission

Abstract

Background: At many centers tumor markers are used to detect disease recurrence and to monitor response to chemotherapy therapy in patients with advanced disease, although the real value of serial observation of marker levels remains disputed. In this study, we evaluated the changes in biochemical and tumor maker (CA 15.3) with respect to Chemotherapy among breast cancer patients.
Aim: The present study was aimed to ascertain the changes in biochemical and tumor maker (CA 15.3) with respect to Chemotherapy among breast cancer patients.
Material & Methods: 40 breast cancer patients and 10 cancer patient other than breast cancer (control subject) from regional cancer center were studied. All the cancer patients were aged between 27 to 56 years old with BSA and BMI ranged between 1.30-1.98 and 13.06-39.51 respectively. Tumor marker CA 15.3 level was done by ELISA, haematological test was measured by cell counter and biochemical assay was measured by Autoanalyzer. Tumor size was measured before and after chemotherapy. Patients were followed 6 years. Survival at 6 years is 60%. The data were analyzed using SPSS (20.0).
Results: The result revealed that as compared to control patients the CA 15.3 maker was statistically significantly higher among breast cancer patients in before as well as in after chemotherapy cycles as well as it accessed the normal range of CA 15.3 (9-36 U/ml). Further, results of Chi-square test revealed statistically significant changes in serum parameters after chemotherapy. Glucose, urea, creatinine, bilirubin (total), bilirubin (direct), ALT (Alanine amino transferase), AST (Aspartate amino transferase), ALP (Alkaline phosphatase) and globulin were found to be significantly increase whereas, CA (15.3), WBC, Hb (haemoglobin), platelets, serum serum sodium, serum potassium, total protein and albumin were found to be significantly decreased, after chemotherapy. 83.3% tumour reduction in case group reported. The 6-year overall survival was 51% in the case group. Overall survival in operated group was 49.4 % and non-operated group was 52.1%.
Conclusion: It is concluded that CA (15.3) is specific and sensitive maker for breast cancer. Further, prominent fluctuations in serum parameters due to chemotherapy specify consequent side-effects among breast cancer patients.

Keywords:
Chemotherapy, CA (15.3), breast cancer, AST, ALT, ALP, T. Protein


How to cite : Chandel P, Uraon H, Choudhary V, Effect of Chemotherapy on Tumor Marker (Ca 15.3) and Serum in Breast Cancer Patients of Southern Eastern Region of Chhattisgarh; 6 Years Follow up Study. Int J Clin Biochem Res 2016;3():16-22

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.